WO2003087831A3 - Proteins involved in breast cancer - Google Patents

Proteins involved in breast cancer Download PDF

Info

Publication number
WO2003087831A3
WO2003087831A3 PCT/GB2003/001559 GB0301559W WO03087831A3 WO 2003087831 A3 WO2003087831 A3 WO 2003087831A3 GB 0301559 W GB0301559 W GB 0301559W WO 03087831 A3 WO03087831 A3 WO 03087831A3
Authority
WO
WIPO (PCT)
Prior art keywords
breast cancer
proteins involved
diagnosis
therapy
effectiveness
Prior art date
Application number
PCT/GB2003/001559
Other languages
French (fr)
Other versions
WO2003087831A2 (en
Inventor
Lyndsey J Hudson
Alasdair Craig Stamps
Jonathan Alexander Terrett
Original Assignee
Oxford Glycosciences Uk Ltd
Lyndsey J Hudson
Alasdair Craig Stamps
Jonathan Alexander Terrett
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Oxford Glycosciences Uk Ltd, Lyndsey J Hudson, Alasdair Craig Stamps, Jonathan Alexander Terrett filed Critical Oxford Glycosciences Uk Ltd
Priority to AU2003222604A priority Critical patent/AU2003222604A1/en
Publication of WO2003087831A2 publication Critical patent/WO2003087831A2/en
Publication of WO2003087831A3 publication Critical patent/WO2003087831A3/en

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57415—Specifically defined cancers of breast
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Abstract

The present invention provides methods and compositions for the screening, diagnosis and therapy of breast cancer, for monitoring the effectiveness of breast cancer treatment, and for drug development.
PCT/GB2003/001559 2002-04-11 2003-04-10 Proteins involved in breast cancer WO2003087831A2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2003222604A AU2003222604A1 (en) 2002-04-11 2003-04-10 Proteins involved in breast cancer

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB0208331A GB0208331D0 (en) 2002-04-11 2002-04-11 Proteins
GB0208331.9 2002-04-11

Publications (2)

Publication Number Publication Date
WO2003087831A2 WO2003087831A2 (en) 2003-10-23
WO2003087831A3 true WO2003087831A3 (en) 2004-07-29

Family

ID=9934645

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/GB2003/001559 WO2003087831A2 (en) 2002-04-11 2003-04-10 Proteins involved in breast cancer

Country Status (3)

Country Link
AU (1) AU2003222604A1 (en)
GB (1) GB0208331D0 (en)
WO (1) WO2003087831A2 (en)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005124357A1 (en) * 2004-06-18 2005-12-29 Roche Diagnostics Gmbh Use of protein elongation factor-1-alpha-1 as a marker for breast cancer
US7807789B2 (en) * 2004-12-21 2010-10-05 Cell Signaling Technology, Inc. Reagents for the detection of protein phosphorylation in EGFR-signaling pathways
WO2006116541A2 (en) * 2005-04-27 2006-11-02 Caprion Pharmaceuticals, Inc. Tat-002 and methods of assessing and treating cancer
GB0520067D0 (en) * 2005-10-01 2005-11-09 Cancer Rec Tech Ltd Treatment of cancer
GB0611116D0 (en) * 2006-06-06 2006-07-19 Oxford Genome Sciences Uk Ltd Proteins
WO2008005556A2 (en) * 2006-07-07 2008-01-10 9183-4663 Quebec Incorporated Tat-048 and methods of assessing and treating cancer
GB0621279D0 (en) * 2006-10-26 2006-12-06 Nat Blood Service Binding site
CA2693098C (en) 2007-07-19 2019-06-18 Yasemin Ataman-Onal Dosage method for the carcino-embryonic antigen and the carbohydrate 19-9 antigen to hepatic fatty acid-binding protein for the diagnosis of colorectal cancer
FR2919065B1 (en) 2007-07-19 2009-10-02 Biomerieux Sa METHOD FOR DETERMINING APOLIPOPROTEIN AI FOR IN VITRO DIAGNOSIS OF COLORECTAL CANCER
FR2919061B1 (en) 2007-07-19 2009-10-02 Biomerieux Sa METHOD OF DOSING PLASTINE-I FOR IN VITRO DIAGNOSIS OF COLORECTAL CANCER.
FR2919064B1 (en) 2007-07-19 2009-10-02 Biomerieux Sa METHOD OF ASSAYING APOLIPOPROTEIN ALL FOR IN VITRO DIAGNOSIS OF COLORECTAL CANCER
FR2919063B1 (en) 2007-07-19 2009-10-02 Biomerieux Sa METHOD OF DETERMINING LEUCOCYTE ELASTASE INHIBITOR FOR IN VITRO DIAGNOSIS OF COLORECTAL CANCER.
FR2919062B1 (en) 2007-07-19 2009-10-02 Biomerieux Sa METHOD OF DETERMINING AMINOACYLASE 1 FOR IN VITRO DIAGNOSIS OF COLORECTAL CANCER.
FR2919060B1 (en) * 2007-07-19 2012-11-30 Biomerieux Sa METHOD OF DETERMINING EZRINE FOR IN VITRO DIAGNOSIS OF COLORECTAL CANCER
CN101925364B (en) * 2007-11-27 2014-04-30 不列颠哥伦比亚大学 14-3-3 antagonists for prevention and treatment of arthritis
FR2933773B1 (en) 2008-07-10 2013-02-15 Biomerieux Sa METHOD FOR DETERMINING THE ISOMERASE DISULFIDE PROTEIN FOR IN VITRO DIAGNOSIS OF COLORECTAL CANCER
FR2940291B1 (en) * 2008-12-23 2012-12-21 Isp Investments Inc PEPTIDE DERIVED FROM HMG-COA REDUCTASE AND COSMETIC OR PHARMACEUTICAL COMPOSITION CONTAINING THE SAME
FR2940125B1 (en) * 2008-12-23 2013-03-22 Isp Investments Inc COSMETIC OR PHARMACEUTICAL SOOTHING COMPOSITION COMPRISING AN ACTIVATOR PEPTIDE OF HMG-COA REDUCTASE
EP2406633B1 (en) 2009-03-11 2019-01-16 Augurex Life Sciences Corp. Compositions and methods for characterizing arthritic conditions
FR2944445B1 (en) 2009-04-15 2013-08-16 Isp Investments Inc COSMETIC AND / OR PHARMACEUTICAL COMPOSITION COMPRISING A SOOTHING PEPTIDE HYDROLYZATE
FR2944526B1 (en) 2009-04-15 2013-05-10 Isp Investments Inc COSMETIC AND / OR PHARMACEUTICAL COMPOSITION COMPRISING A PEPTIDE HYDROLYZATE CAPABLE OF STRENGTHENING BARRIER FUNCTION
US8933036B2 (en) 2009-04-15 2015-01-13 Isp Investments Inc. Cosmetic and/or pharmaceutical composition comprising a yeast peptide hydrolysate and use of the yeast peptide hydrolysate as an active agent for strengthening hair
US9765380B2 (en) * 2010-12-08 2017-09-19 Expression Pathology, Inc. Truncated HER2 SRM/MRM assay
WO2013056377A1 (en) 2011-10-21 2013-04-25 Augurex Life Sciences Corporation Antigens derived from citrullinated 14-3-3 and uses thereof in the diagnosis of rheumatoid arthritis
ES2526468B2 (en) * 2013-06-07 2015-08-07 Universidad Complutense De Madrid Method of selection of specific antibodies of European hake (Merluccius merluccius) to assign individuals to their populations according to whether they are of Atlantic origin or of Mediterranean origin.
GB201520568D0 (en) 2015-11-23 2016-01-06 Immunocore Ltd Peptides
GB201520550D0 (en) 2015-11-23 2016-01-06 Immunocore Ltd & Adaptimmune Ltd Peptides
GB201520546D0 (en) * 2015-11-23 2016-01-06 Immunocore Ltd & Adaptimmune Ltd Peptides
US10537576B2 (en) 2015-12-09 2020-01-21 Expression Pathology, Inc. Methods for treating Her2-positive breast cancer
IT202000016807A1 (en) * 2020-07-10 2022-01-10 Humanitas Mirasole Spa PEPTIDES ASSOCIATED WITH CANCER AND THEIR USE

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS626169A (en) * 1985-07-03 1987-01-13 Mochida Pharmaceut Co Ltd Reagent for diagnosing cancer
WO2001063288A1 (en) * 2000-02-25 2001-08-30 Oxford Glycosciences (Uk) Ltd. Diagnosis of breast cancer using bcmp-81 as marker
WO2001062914A1 (en) * 2000-02-25 2001-08-30 Oxford Glycosciences (Uk) Ltd. Bcmp 84, a protein associated to breast cancer

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS626169A (en) * 1985-07-03 1987-01-13 Mochida Pharmaceut Co Ltd Reagent for diagnosing cancer
WO2001063288A1 (en) * 2000-02-25 2001-08-30 Oxford Glycosciences (Uk) Ltd. Diagnosis of breast cancer using bcmp-81 as marker
WO2001062914A1 (en) * 2000-02-25 2001-08-30 Oxford Glycosciences (Uk) Ltd. Bcmp 84, a protein associated to breast cancer
WO2001062784A2 (en) * 2000-02-25 2001-08-30 Oxford Glycosciences (Uk) Ltd. Use of breast cancer associated membrane proteins (bcmp) for treatment, prophylaxis and diagnosis of breast cancer

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
BETTA P G ET AL: "CORRELATION OF PROLIFERATIVE ACTIVITY WITH PATHOLOGICAL FEATURES IN BREAST CARCINOMA", EUROPEAN JOURNAL OF GYNAECOLOGICAL ONCOLOGY, vol. 10, no. 6, 1989, pages 433 - 437, XP008025440, ISSN: 0392-2936 *
DATABASE EMBL [online] EBI; 13 June 2001 (2001-06-13), STRAUSBERG R: "Homosapiens, transferrin receptor (p90, CD71), clone MGC:3151, IMAGE:3354176, mRNA, complete cds.", XP002264332, retrieved from HTTP://WWW.EBI.AC.UK Database accession no. BC001188 *
DATABASE WPI Section Ch Week 198707, Derwent World Patents Index; Class B04, AN 1987-047433, XP002264333 *
YANG DING CHENG ET AL: "Expression of transferrin receptor and ferritin H-chain mRNA are associated with clinical and histopathological prognostic indicators in breast cancer", ANTICANCER RESEARCH, vol. 21, no. 1B, January 2001 (2001-01-01), pages 541 - 550, XP008025431, ISSN: 0250-7005 *

Also Published As

Publication number Publication date
WO2003087831A2 (en) 2003-10-23
AU2003222604A1 (en) 2003-10-27
AU2003222604A8 (en) 2003-10-27
GB0208331D0 (en) 2002-05-22

Similar Documents

Publication Publication Date Title
WO2003087831A3 (en) Proteins involved in breast cancer
ZA200409492B (en) Compositions and methods for the diagnosis and treatment of tumor.
AU2003205077A1 (en) Imaging agents and methods of imaging naaladase of psma
WO2004030615A8 (en) Compositions and methods for the diagnosis and treatment of tumor
EP1571968A3 (en) Compositions and methods for the diagnosis and treatment of tumor
WO2004016225A8 (en) Compositions and methods for the diagnosis and treatment of tumor
WO2004045516A9 (en) Compositions and methods for the diagnosis and treatment of tumor
WO2003090695A3 (en) TREATMENT OF α-GALACTOSIDASE A DEFICIENCY
EP1571968A4 (en) Compositions and methods for the diagnosis and treatment of tumor
TW200600087A (en) Methods and compositions for treating amyloid-related diseases
UA96115C2 (en) Methods and compositions for treating amyloid-related diseases
AU2003300368A8 (en) Methods and compositions for the diagnosis, prognosis, and treatment of cancer
WO2004008147A3 (en) Diagnosis and prevention of cancer cell invasion
EP1572091A3 (en) Compositions and methods for the diagnosis and treatment of tumor
EP1572091A4 (en) Compositions and methods for the diagnosis and treatment of tumor
WO2004060270A8 (en) Compositions and methods for the diagnosis and treatment of tumor
WO2003057160A8 (en) Compositions and methods for the diagnosis and treatment of tumor
AU2002251366A1 (en) Proteins, genes and their use for diagnosis and treatment of breast cancer
IL151448A0 (en) Proteins
WO2005003154A8 (en) Compositions and methods for the diagnosis and treatment of tumor
WO2007048097A3 (en) Anbrosteeone derivatives and method of use thereof
AU2003237792A1 (en) Compositions and methods for the diagnosis and treatment of tumor
WO2004047757A3 (en) Diagnosing and treating hematopoietic cancers
WO2008026008A8 (en) Protein
WO2004005540A3 (en) Uses of ngal-binding substances in the diagnosis and treatment of cancer diseases

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NI NO NZ OM PH PL PT RO RU SC SD SE SG SK SL TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: JP

WWW Wipo information: withdrawn in national office

Country of ref document: JP